Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteria of IGPs, among which 16 patients primarily recei...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/8580750 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563490507718656 |
|---|---|
| author | Ze Rui Wu Yong Zhang Lin Cai Shao Jian Lin Zhi Peng Su Yong Xu Wei Han Bing Shang Wen Lei Yang Wei Guo Zhao Zhe Bao Wu |
| author_facet | Ze Rui Wu Yong Zhang Lin Cai Shao Jian Lin Zhi Peng Su Yong Xu Wei Han Bing Shang Wen Lei Yang Wei Guo Zhao Zhe Bao Wu |
| author_sort | Ze Rui Wu |
| collection | DOAJ |
| description | Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteria of IGPs, among which 16 patients primarily received bromocriptine (BRC) and the other nine had undergone unsuccessful microsurgery prior to BRC treatment. Results. After a mean follow-up period of 135.5±4.7 months, the clinical symptoms in all patients improved by different degrees. Tumor volume was decreased by a mean of 98.6%, and the tumors of 19 patients had almost completely disappeared. The mean duration of treatment at maximal doses of BRC was 48.5 months. At the last follow-up visit, nineteen patients had normal PRL levels, and 14 of these patients had received the low-dose BRC treatment (at an average of 2.9±0.3 mg/d). Younger patients < 25 years had a significantly higher rate of persistent hyperprolactinemia after long-term BRC treatment (p=0.043). Conclusion. DAs are a first-line therapy for IGPs because they can effectively achieve long-term control in both shrinking tumor volume and normalizing the PRL level, and majority of patients need low-dose DA maintenance. Younger patients are prone to persistent hyperprolactinemia despite long-term DA treatment. |
| format | Article |
| id | doaj-art-58d4856b04d74c5ebc9c9dc59aeb05bc |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-58d4856b04d74c5ebc9c9dc59aeb05bc2025-02-03T01:20:04ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/85807508580750Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year FollowupZe Rui Wu0Yong Zhang1Lin Cai2Shao Jian Lin3Zhi Peng Su4Yong Xu Wei5Han Bing Shang6Wen Lei Yang7Wei Guo Zhao8Zhe Bao Wu9Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, ChinaDepartment of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, ChinaDepartment of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, ChinaDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, ChinaDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, ChinaObjective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteria of IGPs, among which 16 patients primarily received bromocriptine (BRC) and the other nine had undergone unsuccessful microsurgery prior to BRC treatment. Results. After a mean follow-up period of 135.5±4.7 months, the clinical symptoms in all patients improved by different degrees. Tumor volume was decreased by a mean of 98.6%, and the tumors of 19 patients had almost completely disappeared. The mean duration of treatment at maximal doses of BRC was 48.5 months. At the last follow-up visit, nineteen patients had normal PRL levels, and 14 of these patients had received the low-dose BRC treatment (at an average of 2.9±0.3 mg/d). Younger patients < 25 years had a significantly higher rate of persistent hyperprolactinemia after long-term BRC treatment (p=0.043). Conclusion. DAs are a first-line therapy for IGPs because they can effectively achieve long-term control in both shrinking tumor volume and normalizing the PRL level, and majority of patients need low-dose DA maintenance. Younger patients are prone to persistent hyperprolactinemia despite long-term DA treatment.http://dx.doi.org/10.1155/2016/8580750 |
| spellingShingle | Ze Rui Wu Yong Zhang Lin Cai Shao Jian Lin Zhi Peng Su Yong Xu Wei Han Bing Shang Wen Lei Yang Wei Guo Zhao Zhe Bao Wu Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup International Journal of Endocrinology |
| title | Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup |
| title_full | Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup |
| title_fullStr | Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup |
| title_full_unstemmed | Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup |
| title_short | Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup |
| title_sort | long term clinical outcomes of invasive giant prolactinomas after a mean ten year followup |
| url | http://dx.doi.org/10.1155/2016/8580750 |
| work_keys_str_mv | AT zeruiwu longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT yongzhang longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT lincai longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT shaojianlin longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT zhipengsu longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT yongxuwei longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT hanbingshang longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT wenleiyang longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT weiguozhao longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup AT zhebaowu longtermclinicaloutcomesofinvasivegiantprolactinomasafterameantenyearfollowup |